3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Unknown
3
Completed
3
Withdrawn
1
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
14
Brain Neoplasms
10
Carcinoma, Hepatocellular
9
Neoplasm Metastasis
7
Neoplasms
6
Pancreatic Neoplasms
5
Lung Neoplasms
5
Colorectal Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Melanoma
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Glioblastoma
2
Adenocarcinoma of Lung
2
Triple Negative Breast Neoplasms
1
Sarcoma
1
Recurrence
1
Radiotherapy
1
Prostate Cancer Metastatic
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Liver Neoplasms
1
Liver Diseases
1
Kidney Neoplasms
1
Glioma
1
Carcinoma, Transitional Cell
1
Carcinoma, Merkel Cell
1
Interventions
Dexamethasone
14
Rituximab
6
Cytarabine
5
venetoclax
4
Lenalidomide
4
Bortezomib
4
Bendamustine Hydrochloride
4
selinexor
3
pomalidomide
3
pembrolizumab
3
ibrutinib
3
fludarabine
3
carfilzomib
3
Paclitaxel
3
Gemcitabine
3
Drug Therapy
3
Cyclophosphamide
3
Calcium Dobesilate
3
ixazomib
2
gilteritinib
2
fludarabine phosphate
2
elotuzumab
2
daratumumab
2
belinostat
2
Tablets
2
Surveys and Questionnaires
2
Panobinostat
2
Oxaliplatin
2
Granulocyte Colony-Stimulating Factor
2
Etoposide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Recurrence
×
Radiosurgery
×
Clear all
NCT05900908
2025-04-10
PATHWAyS
GT Medical Technologies, Inc.
Phase 4
Withdrawn